Sofia Cárdenas1, Cecilia Colombero1, Laura Panelo2, Rambabu Dakarapu3, John R Falck3, Monica A Costas2, Susana Nowicki4. 1. Centro de Investigaciones Endocrinológicas "Dr. Cesar Bergada" (CEDIE) CONICET-FEI-División de Endocrinología, Hospital de Niños "Ricardo Gutierrez", Gallo 1330, C1425EFD Buenos Aires, Argentina. 2. Laboratorio de Biología Molecular y Apoptosis, Instituto de Investigaciones Médicas Alfredo Lanari, IDIM-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Combatientes de Malvinas 3150, C1427ARN Buenos Aires, Argentina. 3. Department of Biochemistry, UT Southwestern Medical Center, Dallas, TX 75390, United States of America. 4. Centro de Investigaciones Endocrinológicas "Dr. Cesar Bergada" (CEDIE) CONICET-FEI-División de Endocrinología, Hospital de Niños "Ricardo Gutierrez", Gallo 1330, C1425EFD Buenos Aires, Argentina. Electronic address: snowicki@cedie.org.ar.
Abstract
PURPOSE: Recent studies have shown that 20-hydroxyeicosatetraenoic acid (20-HETE) is a key molecule in sustaining androgen-mediated prostate cancer cell survival. Thus, the aim of this study was to determine whether 20-HETE can affect the metastatic potential of androgen-insensitive prostate cancer cells, and the implication of the newly described 20-HETE receptor, GPR75, in mediating these effects. METHODS: The expression of GPR75, protein phosphorylation, actin polymerization and protein distribution were assessed by western blot and/or fluorescence microscopy. Additionally, in vitro assays including epithelial-mesenchymal transition (EMT), metalloproteinase-2 (MMP-2) activity, scratch wound healing, transwell invasion and soft agar colony formation were used to evaluate the effects of 20-HETE agonists/antagonists or GPR75 gene silencing on the aggressive features of PC-3 cells. RESULTS: 20-HETE (0.1 nM) promoted the acquisition of a mesenchymal phenotype by increasing EMT, the release of MMP-2, cell migration and invasion, actin stress fiber formation and anchorage-independent growth. Also, 20-HETE augmented the expression of HIC-5, the phosphorylation of EGFR, NF-κB, AKT and p-38 and the intracellular redistribution of p-AKT and PKCα. These effects were impaired by GPR75 antagonism and/or silencing. Accordingly, the inhibition of 20-HETE formation with N-hydroxy-N'-(4-n-butyl-2-methylphenyl) formamidine (HET0016) elicited the opposite effects. CONCLUSIONS: The present results show for the first time the involvement of the 20-HETE-GPR75 receptor in the activation of intracellular signaling known to be stimulated in cell malignant transformations leading to the differentiation of PC-3 cells towards a more aggressive phenotype. Targeting the 20-HETE/GPR75 pathway is a promising and novel approach to interfere with prostate tumor cell malignant progression.
PURPOSE: Recent studies have shown that 20-hydroxyeicosatetraenoic acid (20-HETE) is a key molecule in sustaining androgen-mediated prostate cancer cell survival. Thus, the aim of this study was to determine whether 20-HETE can affect the metastatic potential of androgen-insensitive prostate cancer cells, and the implication of the newly described 20-HETE receptor, GPR75, in mediating these effects. METHODS: The expression of GPR75, protein phosphorylation, actin polymerization and protein distribution were assessed by western blot and/or fluorescence microscopy. Additionally, in vitro assays including epithelial-mesenchymal transition (EMT), metalloproteinase-2 (MMP-2) activity, scratch wound healing, transwell invasion and soft agar colony formation were used to evaluate the effects of 20-HETE agonists/antagonists or GPR75 gene silencing on the aggressive features of PC-3 cells. RESULTS:20-HETE (0.1 nM) promoted the acquisition of a mesenchymal phenotype by increasing EMT, the release of MMP-2, cell migration and invasion, actin stress fiber formation and anchorage-independent growth. Also, 20-HETE augmented the expression of HIC-5, the phosphorylation of EGFR, NF-κB, AKT and p-38 and the intracellular redistribution of p-AKT and PKCα. These effects were impaired by GPR75 antagonism and/or silencing. Accordingly, the inhibition of 20-HETE formation with N-hydroxy-N'-(4-n-butyl-2-methylphenyl) formamidine (HET0016) elicited the opposite effects. CONCLUSIONS: The present results show for the first time the involvement of the 20-HETE-GPR75 receptor in the activation of intracellular signaling known to be stimulated in cell malignant transformations leading to the differentiation of PC-3 cells towards a more aggressive phenotype. Targeting the 20-HETE/GPR75 pathway is a promising and novel approach to interfere with prostate tumor cell malignant progression.
Authors: Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang Journal: Cancer Chemother Pharmacol Date: 2010-12-01 Impact factor: 3.333
Authors: Meng Guo; Richard J Roman; Joseph D Fenstermacher; Stephen L Brown; John R Falck; Ali S Arbab; Paul A Edwards; A Guillermo Scicli Journal: J Pharmacol Exp Ther Date: 2005-12-13 Impact factor: 4.030
Authors: Paul Sved; Kieran F Scott; Duncan McLeod; Nicholas J C King; Jas Singh; Tania Tsatralis; Blagoy Nikolov; John Boulas; Laxman Nallan; Michael H Gelb; Mila Sajinovic; Garry G Graham; Pamela J Russell; Qihan Dong Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: Tsuneo Ishizuka; Jennifer Cheng; Harpreet Singh; Marco D Vitto; Vijay L Manthati; John R Falck; Michal Laniado-Schwartzman Journal: J Pharmacol Exp Ther Date: 2007-10-18 Impact factor: 4.030
Authors: Kevin Agostinucci; Rebecca Hutcheson; Sakib Hossain; Jonathan V Pascale; Elizabeth Villegas; Frank Zhang; Adeniyi Michael Adebesin; John R Falck; Sachin Gupte; Victor Garcia; Michal Laniado Schwartzman Journal: J Hypertens Date: 2022-03-01 Impact factor: 4.844
Authors: Ankit Gilani; Kevin Agostinucci; Sakib Hossain; Jonathan V Pascale; Victor Garcia; Adeniyi Michael Adebesin; John R Falck; Michal Laniado Schwartzman Journal: Prostaglandins Other Lipid Mediat Date: 2020-10-01 Impact factor: 3.072